Cooper Pharma Announces Launch of FLUBOLIC (Fluoxymesterone 5mg Tablets)


(MENAFN- ForPressRelease) 14 Cooper Pharma today announced that one of its wholly owned hormone product FLUBOLIC that has launched in head office, Delhi, India.
Fluoxymesterone Tablet is a man-made form of testosterone, a naturally occurring sex hormone that is produced in a man's testicles. Small amounts of testosterone are also produced in a woman's ovaries and adrenal system.
Fluoxymesterone Tablet is used in men and boys to treat conditions caused by a lack of this hormone, such as delayed puberty or other hormonal imbalances.
Fluoxymesterone Tablet is also used in women to treat breast cancer that has spread to other parts of the body. Fluoxymesterone 5 MG Oral Tablet treats only the symptoms of metastatic breast cancer but does not treat the cancer itself.
Fluoxymesterone Tablet may also be used for purposes not listed in Fluoxymesterone 5 MG Oral Tablet guide.

About Cooper Pharma Limited (Since 1959)
Cooper Pharma is a legit manufacturing pharmaceutical company and makes its speciality in leading generics/hormones. An integrated business and an extremely skilled team enable us to deliver quality products on time at affordable prices. It provides high quality, affordable products trusted by customers and patients in over 25 states of India. We are approved globally in the level of documentation accredited by various regulatory authorities like WHO-GMP, cGMP and ISO certified company. We also have regulatory approvals from over 25 countries across the world.

Company :-Cooper Pharma Limited

User :- akhil ary

Email :

Phone :-9910777498

Mobile:- 9910777498

Url :- https://www.cooperpharma.com/export-product/hormones/Fluoxymesterone-Tablets


MENAFN0910201900703206ID1099103915


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.